News >

Molecular Testing Needed to Inform CRC Treatment Decisions

Kristi Rosa
Published: Monday, Feb 25, 2019

Michael J. Overman, MD

Michael J. Overman, MD
Physicians must perform molecular testing in each patient with metastatic colorectal cancer (mCRC) as early as possible in order to identify subsets within the disease, as this information can have a prognostic impact in terms of treatment, said Michael Overman, MD.

during the 2019 State of the Science Summit™ on Gastrointestinal Cancers, Overman, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, highlighted data from pivotal trials presented at the 2019 Gastrointestinal Cancers Symposium and discussed where research efforts should be focused to improve the treatment of patients with CRC.

OncLive: What are the clinical implications of the CCTG CO.26 findings?

Overman: This was a randomized clinical trial from Canada that examined the idea of combination immunotherapy in MSS CRC. Specifically, it looked at the combination of durvalumab (Imfinzi) and tremelimumab—a PD-L1–targeted agent and a CTLA-4–targeted agent—and compared that with best supportive care.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication